Cofrogliptin vs Trelagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Cofrogliptin

Marketed by Haisco Pharmaceutical Group

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04556851 · Phase 3 · completed

This randomized, double-blind, placebo-controlled trial enrolled 476 patients and measured change in HbA1c, a standard efficacy measure in diabetes, at 24 weeks. Both HSK7653 doses lowered HbA1c significantly more than placebo (p<0.0001), meeting the trial's primary goal.

Next expected readout: June 2027 · NCT07122102 (registry estimate)

Reported efficacy

HbA1c Change From Baseline at Week 24 (Baseline and week 24): HbA1c change from baseline to week 24 (LS mean, SE): cofrogliptin (HSK7653) 10 mg -0.96% (0.063), 25 mg -0.99% (0.064), linagliptin 5 mg -1.07% (0.065); non-inferiority margin of 0.4% met for both cofrogliptin doses vs linagliptin (met)

Result source: NCT04564872

Trelagliptin · Zafatek

Marketed by Teijin and partners

Phase 3 in Type 2 Diabetessmall molecule
Weak signal

NCT01431807 · Phase 3 · completed

This was a single-group, open-label study with no randomization, blinding, or comparator arm, despite enrolling 680 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07073768 (registry estimate)

Reported efficacy

Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)); Number of Participants Who Had One or More Treatment Emergent Adverse Event (TEAE) Before the Start of Study Drug Administration in Treatment Period II (Up to Week 12); Number of Participants Who Had One or More TEAE Occurred After 1st Dose of Trelagliptin 25 mg Tablet (Up to Week 54): Change From Baseline in HbA1c at the End of Treatment Period I (Baseline (Week 0) and end of Treatment Period I (Up to Week 12)): Trelagliptin 25 mg -0.71 Percent HbA1c (Standard Error 0.087) vs Placebo and Trelagliptin 25 mg 0.01 Percent HbA1c (Standard Error 0.089) (met)

Result source: NCT02512068

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCofrogliptinTrelagliptin
HbA1c, change-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872
-0.7% vs 0.0%−0.7 vs placebo25 mg · wk 12 · n 55NCT02512068
4 other results
  • -0.7% vs 0.0% 25 mg · wk 12 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6% vs -0.1% 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.5% vs 0.0% 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.2% vs 0.1% 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068
Body weight, change (kg)—Not posted · NCT04564872—Not posted · NCT03940183
HbA1c below 7%—Not posted · NCT04564872—Not posted · NCT03940183
Fasting plasma glucose, change—Not posted · NCT04564872-0.9 vs -0.0−0.9 vs placebo25 mg · wk 12 · n 55NCT02512068
3 other results
  • -0.7 vs -0.2 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6 vs -0.1 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.7 vs 0.1 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068
3-point MACE (% with event)—Not posted · NCT04564872—Not posted · NCT03940183

HbA1c, change

Cofrogliptin
-1.0% vs -1.1%avs linagliptin 5 mgcofrogliptin (HSK7653) 25 mg · wk 24NCT04564872
1 other result
  • -1.0% vs -1.1% cofrogliptin (HSK7653) 10 mg · wk 24 · Phase 3 · primary NCT04564872
Trelagliptin
-0.7% vs 0.0%−0.7 vs placebo25 mg · wk 12 · n 55NCT02512068
4 other results
  • -0.7% vs 0.0% 25 mg · wk 12 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6% vs -0.1% 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.5% vs 0.0% 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.2% vs 0.1% 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068

Body weight, change (kg)

Cofrogliptin
—Not posted · NCT04564872
Trelagliptin
—Not posted · NCT03940183

HbA1c below 7%

Cofrogliptin
—Not posted · NCT04564872
Trelagliptin
—Not posted · NCT03940183

Fasting plasma glucose, change

Cofrogliptin
—Not posted · NCT04564872
Trelagliptin
-0.9 vs -0.0−0.9 vs placebo25 mg · wk 12 · n 55NCT02512068
3 other results
  • -0.7 vs -0.2 25 mg · wk 8 · n 55 · Phase 3 · secondary NCT02512068
  • -0.6 vs -0.1 25 mg · wk 4 · n 55 · Phase 3 · secondary NCT02512068
  • -0.7 vs 0.1 25 mg · wk 2 · n 55 · Phase 3 · secondary NCT02512068

3-point MACE (% with event)

Cofrogliptin
—Not posted · NCT04564872
Trelagliptin
—Not posted · NCT03940183
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Cofrogliptin: 0 of 4 rows · Trelagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCofrogliptinTrelagliptin
Dropout rate—
21.8%25 mga
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
0%
NCT03014479 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs—
14.5%25 mga
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
0%
NCT03014479 · Phase 4 · registry result, not featured evidence
Serious AEs—
41.8%25 mga
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
1.8%
NCT03014479 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs—
25 mga
nasopharyngitis 43.6% (placebo 33.3%)
fall 21.8% (placebo 10.4%)
hypoglycaemia 21.8% (placebo 14.6%)
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
show 1 more result
viral upper respiratory tract infection 3.6%
NCT03014479 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cofrogliptin

HbA1c -0.59% @ 24wk25 mg
absolute change · percentage points
No placebo or comparator arm
NCT04556851 · Phase 3 · sponsor-reported, not registry data
show 1 more result
-0.63% @ 24wkcofrogliptin (HSK7653) 10 mg
NCT04556851 · Phase 3 · sponsor-reported, not registry data

Trelagliptin

HbA1c -0.76% (n=55) vs -0.74% (n=52) placebo @ 52wk25 mg
absolute change · percentage points
At the End of Treatment Period II
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3
Fasting Plasma Glucose -0.72 vs 0.13 placebo mmol/L @ 2wk25 mg
absolute change · mmol/L
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -12.9 mg/dL as posted
show 3 more results
-0.63 vs -0.14 placebo mmol/L @ 4wk*25 mg
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -11.3 mg/dL as posted
-0.7 vs -0.24 placebo mmol/L @ 8wk*25 mg
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -12.7 mg/dL as posted
-0.88 vs -0.02 placebo mmol/L @ 12wk*25 mg
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -15.9 mg/dL as posted
Fasting Plasma Glucose -0.79 vs -0.41 placebo mmol/L @ 52wk25 mg
absolute change · mmol/L
At the End of Treatment Period II
NCT02512068 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 · converted to mmol/L from -14.3 mg/dL as posted
DTR-QOL 8.72 vs 6.35 Daily DPP-4 Inhibitors score @ 12wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 2 more results
8.04 vs 4.82 Daily DPP-4 Inhibitors score @ 4wk
NCT03014479 · Phase 4 · registry result, not featured evidence
8.58 vs 6.63 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 1 11.24 vs 7.83 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
10.98 vs 9.12 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 2 5.18 vs 0.39 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
5.94 vs 2.18 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 3 6.15 vs 4.87 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
5.85 vs 7.38 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTR-QOL Factor 4 5.24 vs 3.85 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
8.53 vs 6.71 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence
DTSQs 3.1 vs 1.7 Daily DPP-4 Inhibitors score @ 4wk
absolute change · score
NCT03014479 · Phase 4 · registry result, not featured evidence
show 1 more result
3.1 vs 2.9 Daily DPP-4 Inhibitors score @ 12wk
NCT03014479 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cofrogliptin's landscape · Trelagliptin's landscape